Diabetic Retinopathy - Pipeline Review, H2 2019

Diabetic Retinopathy - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Retinopathy - Pipeline Review, H2 2019, provides an overview of the Diabetic Retinopathy (Metabolic Disorders) pipeline landscape.

Diabetic Retinopathy - Therapeutics DevelopmentPipeline Overview Number of Products under Development for Diabetic Retinopathy, H2 2019

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Retinopathy - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Diabetic Retinopathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Retinopathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Retinopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 7, 9, 4, 61, 13 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 7 and 2 molecules, respectively.

Diabetic Retinopathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Retinopathy (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Diabetic Retinopathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diabetic Retinopathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Retinopathy (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diabetic Retinopathy (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diabetic Retinopathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Diabetic Retinopathy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Diabetic Retinopathy - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Diabetic Retinopathy - Companies Involved in Therapeutics Development
3SBio Inc
A6 Pharmaceuticals
Accuitis Pharmaceuticals Inc
Acucela Inc
Adverum Biotechnologies Inc
Aerie Pharmaceuticals Inc
Akaal Pharma Pty Ltd
Antisense Therapeutics Ltd
Applied Therapeutics Inc
AptaBio Therapeutics Inc
Aptamer Sciences Inc
Araim Pharmaceuticals Inc
Ascentage Pharma Group International
BetaStem Therapeutics Inc
Bio-Thera Solutions Ltd
Boehringer Ingelheim International GmbH
Bonac Corp
CCRP Therapeutics GmbH
Cell Care Therapeutics Inc
Cell Medica Ltd
Charlesson LLC
Clayton Biotechnologies Inc
Coherus BioSciences Inc
Curacle Co Ltd
Dimerix Ltd
Elasmogen Ltd
Emerald Bioscience Inc
Ennovabio
Epigen Biosciences Inc
Everglades Biopharma LLC
F. Hoffmann-La Roche Ltd
Foresee Pharmaceuticals Co Ltd
Formycon AG
Generium
Glycadia Inc
Guangzhou Magpie Pharmaceutical Co Ltd
Hana Pharm Co Ltd
HanAll Biopharma Co Ltd
Hengenix Biotech Inc
iVeena LLC
Kato Pharmaceuticals Inc
Kodiak Sciences Inc
Kowa Co Ltd
Lupin Ltd
Luye Pharma Group Ltd
Mabion SA
Mirae Cell Bio Co Ltd
Mirrx Therapeutics A/S
Nanoscope Therapeutics Inc
NeuBase Therapeutics Inc
NeuMedics Inc
Neurodegeneration Therapeutics Inc
NGM Biopharmaceuticals Inc
Novelty Nobility Inc
OccuRx Pty Ltd
Ocugen Inc
OcuNexus Therapeutics Inc
OliPass Corporation
Opera Therapeutics
Oxurion NV
Palatin Technologies Inc
Panoptes Pharma GesmbH
Phanes Therapeutics Inc
PharmAbcine Inc
Profarma
Promedior Inc
Protheragen Inc
Regeneron Pharmaceuticals Inc
RegenxBio Inc
Retinset SL
Retrotope Inc
Rezolute Inc
Serodus ASA
Singh Biotechnology LLC
Skyran Biologics Inc
Stealth BioTherapeutics Corp
SunBio Inc
Sylentis SAU
Teraclon IDF SL
Translatum Medicus Inc
Valitor Inc
VESSL Therapeutics Ltd
Wntgen LLC
YD Life Science Co
Zih Yuan Tang Biotechnology Co Ltd
Diabetic Retinopathy - Drug Profiles
Diabetic Retinopathy - Dormant Projects
Diabetic Retinopathy - Discontinued Products
Diabetic Retinopathy - Product Development Milestones
Appendix